Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SPN186
MIFTS: 60

Spinal Cord Injury

Categories: Bone diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Spinal Cord Injury

About this section

MalaCards integrated aliases for Spinal Cord Injury:

Name: Spinal Cord Injury 53 58 37 17
Spinal Cord Injuries 42

Characteristics:

Orphanet epidemiological data:

58
spinal cord injury
Prevalence: 1-5/10000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 33 T09.3
UMLS via Orphanet 72 C0037929
Orphanet 58 ORPHA90058
Sources

Summaries for Spinal Cord Injury

About this section
MedlinePlus : 42 Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Spinal Cord Injury, also known as spinal cord injuries, is related to acute cystitis and decubitus ulcer. An important gene associated with Spinal Cord Injury is RTN4IP1 (Reticulon 4 Interacting Protein 1), and among its related pathways/superpathways are PEDF Induced Signaling and Cytokine Signaling in Immune system. The drugs Hydromorphone and Tadalafil have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are behavior/neurological and cellular

NINDS : 53 A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy axons -- extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis

Wikipedia : 74 A spinal cord injury (SCI) is damage to the spinal cord that causes temporary or permanent changes in... more...

Sources

Related Diseases for Spinal Cord Injury

About this section

Diseases related to Spinal Cord Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1001)
# Related Disease Score Top Affiliating Genes
1 acute cystitis 32.7 TNF IL6 CXCL8
2 decubitus ulcer 31.9 TNF MMP9 IL6
3 brain injury 31.5 IL6 GFAP CASP3 BDNF
4 mental depression 31.3 TNF IL6 BDNF
5 hemorrhoid 31.0 TNF NOS2 MMP9
6 traumatic brain injury 30.9 MMP9 IL6 GFAP CASP3 BDNF AQP4
7 pyelonephritis 30.9 TNF IL6 CXCL8
8 constipation 30.9 TNF NOS2 IL6 GDNF BDNF AQP4
9 intestinal obstruction 30.8 TNF IL6 GDNF
10 bone resorption disease 30.8 TNF LEP IL6
11 radiculopathy 30.8 KLK8 IL6 CXCL8
12 chronic ulcer of skin 30.7 TNF MMP9 IL6
13 osteomyelitis 30.7 TNF IL6 CXCL8
14 exanthem 30.6 TNF IL6 CXCL8
15 severe acute respiratory syndrome 30.6 TNF IL6 CXCL8
16 spinal cord disease 30.5 TNF IL6 GFAP GDNF AQP4
17 pulmonary edema 30.5 TNF NOS2 CXCL8
18 neurotic disorder 30.5 TNF IL6 BDNF
19 spinal disease 30.5 TNF IL6 GFAP CASP3
20 pneumonia 30.4 TNF MMP9 IL6 CXCL8
21 major depressive disorder 30.4 TNF LEP IL6 GDNF BDNF
22 complex regional pain syndrome 30.4 TNF IL6 CXCL8
23 sleep disorder 30.4 TNF LEP IL6 BDNF
24 nervous system disease 30.4 TNF NOS2 MMP9 IL6 BDNF
25 prostatitis 30.3 TNF IL6 CXCL8 CASP3
26 bronchitis 30.3 TNF MMP9 IL6 CXCL8
27 arteriovenous malformation 30.3 TNF MMP9 IL6
28 urethritis 30.3 TNF IL6 CXCL8
29 ischemia 30.3 NOS2 GJA1 GFAP CASP3
30 disease of mental health 30.3 TNF LEP IL6 BDNF
31 sleep apnea 30.2 TNF LEP IL6 CXCL8 BDNF
32 neuroma 30.2 IL6 GFAP GDNF AQP4
33 esophagitis 30.1 TNF IL6 CXCL8
34 fasciitis 30.1 TNF IL6 GFAP CXCL8
35 colitis 30.1 TNF NOS2 IL6 CXCL8
36 demyelinating disease 30.1 TNF MMP9 IL6 CSPG4 AQP4
37 myelitis 30.1 TNF MMP9 IL6 CXCL8 AQP4
38 brain edema 30.1 NOS2 MMP9 IL6 GFAP AQP4
39 septic arthritis 30.1 TNF IL6 CXCL8
40 leptin deficiency or dysfunction 30.1 TNF LEP IL6 BDNF
41 toxic shock syndrome 30.1 TNF NOS2 IL6 CXCL8
42 proteasome-associated autoinflammatory syndrome 1 30.1 TNF NOS2 MMP9 IL6 CXCL8
43 cystitis 30.1 TNF NOS2 IL6 GDNF CXCL8 BDNF
44 peritonitis 30.1 TNF NOS2 IL6 CXCL8
45 transverse myelitis 30.1 TNF MMP9 IL6 CXCL8 AQP4
46 amyotrophic lateral sclerosis 1 30.1 TNF NGFR IL6 GFAP GDNF CASP3
47 meningoencephalitis 30.1 TNF IL6 GDNF BDNF
48 cerebral artery occlusion 30.1 TNF NOS2 GDNF BDNF AQP4
49 primary progressive multiple sclerosis 30.0 TNF MMP9 BDNF
50 limb ischemia 30.0 TNF MMP9 IL6

Graphical network of the top 20 diseases related to Spinal Cord Injury:



Diseases related to Spinal Cord Injury
Sources

Symptoms & Phenotypes for Spinal Cord Injury

About this section

MGI Mouse Phenotypes related to Spinal Cord Injury:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 AQP4 BDNF CASP3 GDNF GFAP GJA1
2 cellular MP:0005384 10.42 BDNF CASP3 CSPG4 GDNF GFAP GJA1
3 homeostasis/metabolism MP:0005376 10.41 AQP4 ARG1 BDNF CASP3 CSPG4 GFAP
4 growth/size/body region MP:0005378 10.39 AQP4 BDNF CASP3 CSPG4 GDNF GFAP
5 cardiovascular system MP:0005385 10.36 AQP4 CASP3 GDNF GFAP GJA1 GRIN1
6 mortality/aging MP:0010768 10.36 AQP4 ARG1 BDNF CASP3 GDNF GFAP
7 hematopoietic system MP:0005397 10.34 AQP4 ARG1 CASP3 CSPG4 GDNF GJA1
8 nervous system MP:0003631 10.33 AQP4 ARG1 BDNF CASP3 CSPG4 GDNF
9 digestive/alimentary MP:0005381 10.31 AQP4 BDNF CASP3 GDNF GFAP IL6
10 immune system MP:0005387 10.31 AQP4 ARG1 CASP3 CSPG4 GDNF GFAP
11 endocrine/exocrine gland MP:0005379 10.21 AQP4 BDNF CASP3 GDNF GJA1 IL6
12 integument MP:0010771 10.13 BDNF CASP3 GJA1 IL6 LEP MMP9
13 muscle MP:0005369 10.13 CASP3 GDNF GFAP GJA1 IL6 LEP
14 hearing/vestibular/ear MP:0005377 10.01 AQP4 BDNF CASP3 GJA1 GRIN1 NGFR
15 no phenotypic analysis MP:0003012 9.97 AQP4 BDNF CASP3 CSPG4 GJA1 GRIN1
16 reproductive system MP:0005389 9.96 BDNF CASP3 GDNF GJA1 GRIN1 IL6
17 renal/urinary system MP:0005367 9.92 AQP4 CASP3 GDNF IL6 LEP MMP9
18 respiratory system MP:0005388 9.9 AQP4 BDNF CASP3 GJA1 GRIN1 IL6
19 vision/eye MP:0005391 9.4 AQP4 BDNF CASP3 GFAP GJA1 GRIN1
20 taste/olfaction MP:0005394 9.26 BDNF CASP3 GRIN1 NGFR
Sources

Drugs & Therapeutics for Spinal Cord Injury

About this section

Drugs for Spinal Cord Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 386)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
2
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
5
Amitriptyline Approved Phase 4 50-48-6 2160
6
Perphenazine Approved Phase 4 58-39-9 4748
7
4-Aminopyridine Approved Phase 4 504-24-5 1727
8
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
9
Levetiracetam Approved Phase 4 102767-28-2 441341
10
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
11
Oxcarbazepine Approved Phase 4 28721-07-5 34312
12
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
13
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
14
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
15
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
16
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
17
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
18
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
19
tannic acid Approved Phase 4 1401-55-4
20
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
21
Norepinephrine Approved Phase 4 51-41-2 439260
22
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
23
Droxidopa Approved, Investigational Phase 4 23651-95-8 443940
24
Morphine Approved, Investigational Phase 4 57-27-2 5288826
25
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
26
Mecamylamine Approved, Investigational Phase 4 60-40-2 4032
27
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
28
Baclofen Approved Phase 4 1134-47-0 2284
29
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
31
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
32
Cycloserine Approved Phase 4 68-41-7 401 6234
33
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
34
Glucagon Approved Phase 4 16941-32-5
35
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
36
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
37
Fidaxomicin Approved Phase 4 873857-62-6
38
Vancomycin Approved Phase 4 1404-90-6 14969 441141
39
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
40
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
41
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
42 Anesthetics, General Phase 4
43 Phosphodiesterase 5 Inhibitors Phase 4
44 Phosphodiesterase Inhibitors Phase 4
45 Vasodilator Agents Phase 4
46 Vardenafil Dihydrochloride Phase 4
47 Citrate Phase 4
48 Parasympatholytics Phase 4
49 Muscarinic Antagonists Phase 4
50 Trospium chloride Phase 4 10405-02-4

Interventional clinical trials:

(show top 50) (show all 1430)
# Name Status NCT ID Phase Drugs
1 Assessment of Pregabalin Efficacy for the Treatment and Prevention of At-level Non-evoked and Evoked Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
2 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial Unknown status NCT03169582 Phase 4 Avanafil;Sildenafil
3 An Open, Longitudinal, Prospective, Non-randomized, Self-Controlled Feasibility Study to Investigate the Effect of the ReWalkâ„¢ Device on Mobility Outcomes in Patients With Chronic Spinal Cord Injury. Unknown status NCT01943669 Phase 4
4 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
5 Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
6 A Longitudinal Clinical Feasibility Study to Evaluate the Psychological and Functional Effects of Using the Tobiiâ„¢ Eyegaze System by Inpatients With Tetraplegia Unknown status NCT01943656 Phase 4
7 Early Nerve Reconstruction Approach in Tetraplegic Patients With Dysfunctional Upper Extremity: a Randomized Controlled Trial. Unknown status NCT01579604 Phase 4
8 Analgesic and Hemodynamic Effects of Continuous Epidural Analgesia Compared to Paravertebral Block in Liver Resection Patients Unknown status NCT02909322 Phase 4
9 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
10 The Effect of Botulinum Toxin A in Post Spinal Cord Injury Neuropathic Pain Completed NCT01579500 Phase 4 Botulinum toxin type A;normal saline
11 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed NCT00800462 Phase 4 Oxybutynin Cl;Trospium Cl;Darifenacin Hydrogen Bromide (HBr)
12 A Six Month Randomized Open-Label Trial of Pressure Ulcer Healing With Microcyn® Skin and Wound Care With Preservatives Versus Sterile Saline in Adult Spinal Cord Injury Subjects Completed NCT02001558 Phase 4 Microcyn
13 Melatonin Replacement for Treatment of Sleep Disruption Completed NCT00507546 Phase 4 Ramelteon;Placebo
14 Management of Chronic Pain in Rehabilitation Project I - Management of Chronic Pain in Persons With Spinal Cord Injury Completed NCT00006428 Phase 4 Amitriptyline
15 A Placebo-Controlled, Randomized, Two-Way Cross-Over, Double-Blind, Flexible Dose, Multicenter Study to Evaluate the Efficacy and Safety of Viagra in Male Patients With Traumatic Spinal Cord Injury and Erectile Dysfunction Completed NCT00654082 Phase 4 sildenafil;placebo
16 Double-blind, Cross-over, Placebo Controlled Pilot Study to Characterize the Profile of Those Patients With Spinal Cord Injury Diagnosed by Electrophysiological, Urodynamic and Clinical (ASIA Group) Assessment Who May Respond to Vardenafil Treatment. (LEMDE) Completed NCT00667966 Phase 4 Vardenafil (Levitra, BAY 38-9456), 10 mg;Placebo;Vardenafil (Levitra, BAY 38-9456), 20 mg
17 Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury - a Prospective, Randomized, Controlled, Multicentre Trial of Transanal Irrigation Vs. Conservative Bowel Management Completed NCT00286520 Phase 4
18 Bowel Care and Cardiovascular Function After Spinal Cord Injury Completed NCT01567605 Phase 4 Lidocaine lubricant
19 Omega-3 Supplementation to Increase HDL-c Levels in Those With Tetraplegia Completed NCT01896037 Phase 4
20 Effects of Levetiracetam on Chronic Neuropathic Pain Following Spinal Cord Injury: a Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Completed NCT00252954 Phase 4 Levetiracetam
21 Effect of PTH Combined With Weight-Bearing on Bone Density and Bone Architecture in People With Spinal Cord Injury Completed NCT00826228 Phase 4 teriparatide
22 Symptom-Based Treatment for Neuropathic Pain in Spinal Cord Injured Patients, Randomized Clinical Trial Completed NCT02180880 Phase 4 Pregabalin and Oxcarbazepine
23 The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury Completed NCT02042872 Phase 4 Zoledronic acid
24 A Randomized, Double-blind, Placebo-controlled Cross-over Trial Assessing the Effect of Tadalafil (Cialis) on the Cardiovascular System in Men With Complete Spinal Cord Injury (SCI) at or Above the Sixth Thoracic Level Completed NCT01067391 Phase 4 tadalafil;placebo
25 Botulinum Toxin A for the Treatment of Cervical/Shoulder Pain Following Acute Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
26 A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study Completed NCT00592384 Phase 4 venlafaxine XR;placebo
27 Efficacy and Safety of Bowel Preparations for Colonoscopy in SCI Completed NCT00745095 Phase 4 Neostigmine
28 Core Temperature During Cold Exposure in Persons With Tetraplegia Completed NCT01822535 Phase 4 Midodrine hydrochloride
29 A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury Completed NCT00224029 Phase 4 Oxybutynin transdermal system
30 A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
31 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
32 Does Pretreated Magnesium Protect Against Reperfusion Injury in Liver Transplanted Patients? Completed NCT00994981 Phase 4 magnesium;normal saline
33 A Prospective Randomized Controlled Trial of Standardized C7-T1 Epidural Steroid Injections Versus Targeted Injection Via Cervical Epidural Catheter for the Treatment of Cervical Radicular Pain Completed NCT02095197 Phase 4 Triamcinolone 80mg
34 A Prospective, Randomized, Parallel-group, Multi-center Study to Compare the Occurrence of Urinary Tract Infections in Patients With Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters. Completed NCT00318591 Phase 4
35 Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury Completed NCT02298660 Phase 4 BOTOX
36 Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: a Phase IV, Double-blind, Placebo-controlled Study. Completed NCT02146534 Phase 4 extended release fampridine;Placebo
37 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
38 Evaluation of the Safety of C-Spine Clearance by Emergency Department Triage Nurses (Phase IV) Completed NCT01353352 Phase 4
39 An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
40 A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
41 A Case Series of Patients With Spinal Cord Injury Treated With Standard Therapies and NeuroAiD Recruiting NCT02537899 Phase 4 NeuroAiD
42 An Open-label, Single Centre Prospective Cohort Study to Determine the Effectiveness and Safety of Targin® for Pain Management and Opioid-induced Constipation in Patients With Spinal Cord Injury: Can we Improve Pain and Ameliorate Secondary Complications of Opioid Treatment? Recruiting NCT03179475 Phase 4 Oxycodone Naloxone Combination
43 Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in Spinal Cord Injury (SCI) Recruiting NCT04256603 Phase 4 Gabapentin
44 The Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among Spinal Cord Injury Patients Who Have Yet to Develop Central Pain Recruiting NCT03748290 Phase 4 Pregabalin;Placebo Oral Tablet
45 Utilizing Contrast-enhanced Ultrasound (CEUS) to Assess Critically Hypo Perfused Spinal Cord Tissue After Injury Recruiting NCT04056988 Phase 4 Perflutren Lipid Microsphere
46 Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury Recruiting NCT02922894 Phase 4 Trazodone;Placebo
47 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
48 The Efficacy of Denosumab to Prevent Bone Loss in Ambulatory and Non-ambulatory Motor-Incomplete Patients With Subacute Spinal Cord Injury Recruiting NCT03029442 Phase 4 Denosumab (Prolia)
49 The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury Recruiting NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
50 Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis Recruiting NCT03914677 Phase 4 Mecamylamine Oral Tablet

Search NIH Clinical Center for Spinal Cord Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spinal Cord Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spinal Cord Injury:
Adipose spheroid-derived Schwann cells for the treatment of spinal cord injury
Bone marrow-derived hematopoietic stem cells for spinal cord injury
Cerecellgram-Spine, bone marrow-derived mesenchymal stem cells for treatment of chronic spinal cord injury
GRNOPC1, hESC-derived oligodendrocyte progenitor cells for spinal cord injury
HuCNS-SC, human central nervous system stem cells for neurological diseases
MultiStem, bone marrow-derived cells for neurological disorders
NSI-566, spinal cord stem cells for neurological disorders
RNL-Astrostem, adipose-derived mesenchymal stem cells for treatment of spinal cord injury
Schwann cells for treatment of spinal cord injury
Umbilical cord-derived mesenchymal stem cells for treatment of spinal cord injury
Embryonic/Adult Cultured Cells Related to Spinal Cord Injury:
Schwann-like cells PMIDs: 20083105
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19364066
Bone marrow-derived mesenchymal stem cells
Oligodendrocyte progenitor-like cells PMIDs: 17253955 17996308
Human neural stem cells (HuCNS-SC) PMIDs: 16610769
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Fetal spinal cord stem cells (NSI-566) PMIDs: 22415942 19326469
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080 22017805
Schwann cells PMIDs: 23098734 23186720 16629629
Schwann cells PMIDs: 23098734 23186720 16629629
Umbilical cord-derived mesenchymal stem cells PMIDs: 23942181
Sources

Genetic Tests for Spinal Cord Injury

About this section
Sources

Anatomical Context for Spinal Cord Injury

About this section

MalaCards organs/tissues related to Spinal Cord Injury:

40
Spinal Cord, Bone, Brain, Testes, Bone Marrow, Cortex, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spinal Cord Injury:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
4 Peripheral Nervous System Peripheral Nerve Domain Myelinating Schwann Cells Potential therapeutic candidate
5 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
6 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
7 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
8 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate
Sources

Publications for Spinal Cord Injury

About this section

Articles related to Spinal Cord Injury:

(show top 50) (show all 33114)
# Title Authors PMID Year
1
Efficacy of neural stem cell transplantation for the treatment of patients with spinal cord injury: A protocol of systematic review and meta-analysis. 42 61
32384508 2020
2
The management of emergency spinal surgery during the COVID-19 pandemic in Italy. 42
32323563 2020
3
Perspectives on Spinal Precautions in Patients Who Have Cancer and Spinal Metastasis. 42
32043130 2020
4
Stem-like cells of various origins showed therapeutic effect to improve the recovery of spinal cord injury. 61
32054316 2020
5
Histological and functional outcomes in a rat model of hemisected spinal cord with sustained VEGF/NT-3 release from tissue-engineered grafts. 61
31899965 2020
6
MicroRNA regulatory pattern in spinal cord ischemia-reperfusion injury. 61
32394971 2020
7
Reliable cell purification and determination of cell purity: crucial aspects of olfactory ensheathing cell transplantation for spinal cord repair. 61
32394949 2020
8
The link between olfactory ensheathing cell survival and spinal cord injury repair: a commentary on common limitations of contemporary research. 61
32246630 2020
9
Neuroprotective effects of a ketogenic diet in combination with exogenous ketone salts following acute spinal cord injury. 61
32246640 2020
10
Corrigendum: Three-dimensional bioprinting collagen/silk fibroin scaffold combined with neural stem cells promotes nerve regeneration after spinal cord injury. 61
32246646 2020
11
Effects of durotomy versus myelotomy in the repair of spinal cord injury. 61
32246622 2020
12
Modulation of autophagy for neuroprotection and functional recovery in traumatic spinal cord injury. 61
32209759 2020
13
Decoding epigenetic codes: new frontiers in exploring recovery from spinal cord injury. 61
32209760 2020
14
Collagen scaffold combined with human umbilical cord-mesenchymal stem cells transplantation for acute complete spinal cord injury. 61
32209773 2020
15
Proanthocyanidin promotes functional recovery of spinal cord injury via inhibiting ferroptosis. 61
32474063 2020
16
Mitochondria focused neurotherapeutics for spinal cord injury. 61
32353464 2020
17
Regional Hyperexcitability and Chronic Neuropathic Pain Following Spinal Cord Injury. 61
31955281 2020
18
Learning to promote recovery after spinal cord injury. 61
32353465 2020
19
Recovery of motricity and micturition after transplantation of mesenchymal stem cells in rats subjected to spinal cord injury. 61
32531527 2020
20
Neuroprotective effect of gastrodin in methamphetamine-induced apoptosis through regulating cAMP/PKA/CREB pathway in cortical neuron. 61
32162539 2020
21
Electrical stimulation and denervated muscles after spinal cord injury. 61
31997798 2020
22
Human umbilical cord mesenchymal stem cells to treat spinal cord injury in the early chronic phase: study protocol for a prospective, multicenter, randomized, placebo-controlled, single-blinded clinical trial. 61
31997819 2020
23
Information seeking behavior and perceived health literacy of family caregivers of persons living with a chronic condition. The case of spinal cord injury in Switzerland. 61
32098740 2020
24
MicroRNA-223 targets NLRP3 to relieve inflammation and alleviate spinal cord injury. 61
32417375 2020
25
Multimodal treatment for spinal cord injury: a sword of neuroregeneration upon neuromodulation. 61
31997803 2020
26
Expression of long non-coding RNAs in complete transection spinal cord injury: a transcriptomic analysis. 61
31997824 2020
27
Neuroprotective effect of deferoxamine on erastininduced ferroptosis in primary cortical neurons. 61
31997820 2020
28
Helicopter transport in pediatric trauma: A new methodology using Need for Surgeon Presence to evaluate the necessity of air transport. 61
31806166 2020
29
Shock wave lithotripsy for a renal stone in a tetraplegic patient as a trigger for life-threatening posterior reversible encephalopathy syndrome. 61
32322524 2020
30
Synergy between Acute Intermittent Hypoxia and Task-Specific Training. 61
32412926 2020
31
Alteration of glycinergic receptor expression in lumbar spinal motoneurons is involved in the mechanisms underlying spasticity after spinal cord injury. 61
32339654 2020
32
A Western diet impairs CNS energy homeostasis and recovery after spinal cord injury: Link to astrocyte metabolism. 61
32376475 2020
33
A circRNA derived from linear HIPK3 relieves the neuronal cell apoptosis in spinal cord injury via ceRNA pattern. 61
32247616 2020
34
An elastic gel consisting of natural polyphenol and pluronic for simultaneous dura sealing and treatment of spinal cord injury. 61
32387549 2020
35
Estimating the number of traffic crash-related cervical spine injuries in the United States; An analysis and comparison of national crash and hospital data. 61
32413544 2020
36
Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries. 61
32350120 2020
37
mRNA Profiling for miR-124-mediated Repair in Spinal Cord Injury. 61
32413396 2020
38
MicroRNA‑138‑5p regulates the development of spinal cord injury by targeting SIRT1. 61
32319664 2020
39
Re: Acute Spinal Cord Injury is Associated with Mitochondrial Dysfunction in Mouse Urothelium. 61
32293961 2020
40
Correlation between elevated inflammatory cytokines of spleen and spleen index in acute spinal cord injury. 61
32447026 2020
41
Interlimb conditioning of lumbosacral spinally evoked motor responses after spinal cord injury. 61
32403065 2020
42
Cardiovagal baroreflex gain relates to sensory loss after spinal cord injury. 61
32247945 2020
43
Correlation Between D-Dimer Level and Deep Venous Thrombosis in Patients With Acute Spinal Cord Injuries. 61
31996567 2020
44
Emergency Aortic Control for Pedicle Screw Misplacement During Spinal Fixation. 61
31923600 2020
45
Traveling Material↔Semiotic Environments of Disability, Rehabilitation, and Physical Activity. 61
30585534 2020
46
Intravenous administration of human amniotic mesenchymal stem cells improves outcomes in rats with acute traumatic spinal cord injury. 61
32501888 2020
47
Ginsenoside Rg1-induced activation of astrocytes promotes functional recovery via the PI3K/Akt signaling pathway following spinal cord injury. 61
32259600 2020
48
TNFAIP8 influences the motor function in mice after spinal cord injury (SCI) through meditating inflammation dependent on AKT. 61
32487318 2020
49
Metabolic syndrome is the key determinant of impaired vaginal lubrication in women with chronic spinal cord injury. 61
31983040 2020
50
The N-formyl peptide receptors: contemporary roles in neuronal function and dysfunction. 61
31960798 2020
Sources

Variations for Spinal Cord Injury

About this section
Sources

Expression for Spinal Cord Injury

About this section
Search GEO for disease gene expression data for Spinal Cord Injury.
Sources

Pathways for Spinal Cord Injury

About this section

Pathways related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
PEDF Induced Signaling 63
Show member pathways
 13.63 TNF NOS2 NGFR LEP IL6 GRIN1
2
Cytokine Signaling in Immune system 65
Show member pathways
 13.32 TNF NOS2 MMP9 IL6 GRIN1 GDNF
3
Parkinson disease 36
Show member pathways
 13.14 TNF NOS2 IL6 GRIN1 CASP3 BDNF
4
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.03 TNF NOS2 MMP9 IL6 CXCL8 CASP3
5
Allograft rejection 1 36
Show member pathways
 12.82 TNF IL6 GDNF CXCL8 CASP3
6
Pathways in cancer 36
12.81 NOS2 MMP9 IL6 CXCL8 CASP3
7
IL-17 Family Signaling Pathways 64
Show member pathways
 12.3 TNF MMP9 IL6 CXCL8 CASP3
8
Toll Comparative Pathway 63
Show member pathways
 12.29 TNF NOS2 IL6 CXCL8
10
Salmonella infection (KEGG) 36
12.29 TNF IL6 CXCL8 CASP3
11
Transcriptional misregulation in cancer 36
12.25 NGFR MMP9 IL6 CXCL8
12
Pathogenic Escherichia coli infection 36
12.25 TNF IL6 CXCL8 CASP3
13
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.24 TNF NGFR IL6 CXCL8 BDNF
14
Tuberculosis 36
12.21 TNF NOS2 IL6 CASP3
15
Bacterial infections in CF airways 22
Show member pathways
 12.16 TNF NOS2 IL6 CXCL8
16
Colorectal Cancer Metastasis 63
12.11 TNF NOS2 MMP9 IL6 CASP3
17
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
12.08 NGFR GRIN1 CASP3 BDNF
18
TNF signaling pathway 36
11.96 TNF MMP9 IL6 CASP3
19
AGE-RAGE signaling pathway in diabetic complications 36
11.9 TNF IL6 CXCL8 CASP3
20
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.86 NGFR LEP IL6 GJA1
21
Interleukin-4 and 13 signaling 65
11.86 TNF NOS2 MMP9 IL6 CXCL8
22
TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.78 TNF NGFR BDNF
23
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.77 TNF IL6 GRIN1 GJA1 CXCL8 CASP3
24
Neural Stem Cells and Lineage-specific Markers 64
11.75 GFAP GDNF CSPG4 BDNF
25
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.74 TNF CXCL8 CASP3
26
AGE/RAGE pathway 1
11.67 NOS2 MMP9 CASP3
27
p75(NTR)-mediated signaling 1
Show member pathways
 11.66 RTN4R NGFR CASP3 BDNF
28
Spinal Cord Injury 1
11.66 TNF RTN4R NOS2 NGFR MMP9 LEP
29
LPA receptor mediated events 1
11.64 MMP9 IL6 CXCL8 CASP3
30
Amoebiasis 36
11.64 TNF NOS2 IL6 CXCL8 CASP3 ARG1
31
Lung fibrosis 1
11.61 TNF MMP9 IL6 CXCL8
32
Pertussis 36
11.6 TNF NOS2 IL6 CXCL8 CASP3
33
Malaria 36
11.53 TNF IL6 CXCL8
34
Legionellosis 36
11.53 TNF IL6 CXCL8 CASP3
35
Interleukin-10 signaling 65
11.52 TNF IL6 CXCL8
36
MSP-RON Signaling 63
11.5 TNF NOS2 KLK8
37
amb2 Integrin signaling 1
11.5 TNF MMP9 IL6
38
ATF-2 transcription factor network 1
11.5 NOS2 IL6 CXCL8 ARG1
39
NgR-p75(NTR)-Mediated Signaling 63
11.47 RTN4R NGFR ARG1
40
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.45 TNF NOS2 MMP9 IL6 CXCL8
41
Hepatitis C and Hepatocellular Carcinoma 1
11.44 NOS2 IL6 CXCL8 CASP3
42
14-3-3 and Regulation of BAD Activity 63
11.3 TNF NGFR CASP3
43
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.2 MMP9 IL6 GJA1 CXCL8
44
Transcription factor regulation in adipogenesis 1
11.09 TNF LEP IL6
45
Overview of nanoparticle effects 1
11.01 TNF IL6 CXCL8
46
G-protein signaling_Rap2B regulation pathway 22
11 TNF IL6 GFAP CXCL8 BDNF
Sources

GO Terms for Spinal Cord Injury

About this section

Cellular components related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.87 TNF RTN4R NGFR GRIN1 GJA1 CSPG4
2 extracellular space GO:0005615 9.61 TNF MMP9 LEP KLK8 IL6 GDNF
3 membrane raft GO:0045121 9.56 TNF RTN4R GJA1 CASP3
4 extracellular region GO:0005576 9.4 TNF NGFR MMP9 LEP KLK8 IL6
5 astrocyte end-foot GO:0097450 9.16 GFAP AQP4

Biological processes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.86 NOS2 GJA1 CASP3 ARG1
2 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.82 TNF IL6 BDNF
3 memory GO:0007613 9.81 KLK8 GRIN1 BDNF
4 positive regulation of apoptotic process GO:0043065 9.8 TNF NGFR MMP9 IL6 GRIN1 CASP3
5 neuron projection morphogenesis GO:0048812 9.79 KLK8 GJA1 BDNF
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 TNF LEP IL6
7 regulation of insulin secretion GO:0050796 9.77 TNF NOS2 LEP
8 response to glucocorticoid GO:0051384 9.77 TNF IL6 CASP3
9 learning or memory GO:0007611 9.76 GRIN1 CASP3 BDNF
10 circadian rhythm GO:0007623 9.76 NOS2 NGFR LEP BDNF
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.72 TNF MMP9 GJA1
12 cellular response to amyloid-beta GO:1904646 9.71 NGFR GRIN1 GJA1
13 negative regulation of apoptotic process GO:0043066 9.7 NGFR MMP9 LEP IL6 GDNF CASP3
14 response to wounding GO:0009611 9.67 KLK8 GFAP CASP3 ARG1
15 positive regulation of JAK-STAT cascade GO:0046427 9.65 TNF LEP IL6
16 cellular response to lipopolysaccharide GO:0071222 9.65 TNF NOS2 IL6 CXCL8 ARG1
17 positive regulation of neuroinflammatory response GO:0150078 9.64 TNF IL6
18 regulation of neuroinflammatory response GO:0150077 9.63 MMP9 IL6
19 negative regulation of axon regeneration GO:0048681 9.63 RTN4R KLK8
20 regulation of cytokine production involved in inflammatory response GO:1900015 9.62 NOS2 LEP
21 response to vitamin E GO:0033197 9.61 LEP ARG1
22 neurotrophin TRK receptor signaling pathway GO:0048011 9.61 NGFR CASP3 BDNF
23 positive regulation of receptor binding GO:1900122 9.58 MMP9 BDNF
24 positive regulation of glial cell proliferation GO:0060252 9.58 TNF IL6 GFAP
25 arginine catabolic process GO:0006527 9.57 NOS2 ARG1
26 interleukin-8 secretion GO:0072606 9.52 NOS2 LEP
27 interleukin-6 secretion GO:0072604 9.51 NOS2 LEP
28 prostaglandin secretion GO:0032310 9.49 NOS2 LEP
29 negative regulation of lipid storage GO:0010888 9.13 TNF LEP IL6
30 cytokine-mediated signaling pathway GO:0019221 9.1 TNF NOS2 MMP9 IL6 CXCL8 CASP3

Molecular functions related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 TNF RTN4R RTN4IP1 NOS2 NGFR MMP9
Sources

Sources for Spinal Cord Injury

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....